# US 2016/0355881 A1 · DNA Methylation Analysis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0355881 A1
- Document ID: US20160355881A1
- Status: Published application
- Kind: A1
- Application number: 14/913,862
- Filed: 2014-07-24
- Published: 2016-12-08
- Earliest claimed: 2013-07-24
- Assignees: Brandeis University
- Applicants: Brandeis University
- Inventors: Lawrence J. Wangh; Jesus A Sanchez
- Web page: https://patentgrep.com/patent/US20160355881A1

## CPC

- C12Q 1/6858: Allele-specific amplification
- C12Q 1/6827: for detection of mutation or polymorphism
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

Disclosed herein are methods for determining whether one or more CpG dinucleotides are methylated using Linear After the Exponential Polymerase Chain Reaction (“LATE-PCR”) or Linear-Expo-Linear Polymerase Chain Reaction (“LEL-PCR”).

## Claims

### Claim 1

A method of detecting the methylation status of a CpG dinucleotide located in a target region of a DNA molecule, the method comprising the steps of:
a) contacting the DNA molecule with a solution comprising bisulfate under conditions such that a majority of unmethylated cytosine residues in the DNA molecule are converted to uracil and a majority of methylated cytosine residues in the DNA molecule remain cytosine;
b) amplifying the target region of the bisulfite-treated DNA molecule using LATE-PCR or LEL-PCR to generate an amplification product;
c) determining whether the CpG dinucleotide was converted to uracil in step a).

### Claim 2 (depends on 1)

The method of claim 1, wherein LATE-PCR is used in step b).

### Claim 3 (depends on 1)

The method of claim 1, wherein LEL-PCR is used in step b).

### Claim 4 (depends on 1)

The method of claim 1, wherein TI-PCR is used to perform the LATE-PCR or LEL-PCR amplification.

### Claim 5 (depends on 1)

The method of claim 1, wherein one or more SuperSelective primers are used during the amplification process of step b).

### Claim 6 (depends on 1)

The method of claim 1, wherein the target region encompasses a CpG island.

### Claim 7 (depends on 1)

The method of claim 1, wherein step c) comprises hybridizing the amplification product to a set of Lights-On/Lights-Off probes or to a Lights-Off Only probe and a dsDNA fluorescent dye.

### Claim 8 (depends on 6)

The method of claim 6, wherein a Lights-On probe hybridizes to the amplification product at the position of a CpG dinucleotide.

### Claim 9 (depends on 1)

The method of claim 1, wherein step c) comprises sequencing at least part of the amplification product.

### Claim 10 (depends on 9)

The method of claim 9, wherein the sequencing is performed using an assay selected from the group consisting of chain termination sequencing, sequencing by ligation, sequencing by synthesis, pyrosequencing, ion semiconductor sequencing, single-molecule real-time sequencing, dilute-‘n’-go sequencing and 454 sequencing.

### Claim 11 (depends on 10)

The method of claim 10, wherein the sequencing step comprises dilute-‘n’-go sequencing.

### Claim 12 (depends on 1)

The method of claim 1, wherein the methylation status of more than one CpG dinucleotide located in the target region is detected.

### Claim 13 (depends on 12)

The method of claim 12, wherein step c) comprises hybridizing the amplification product to a first set of Lights-On/Lights-Off probes and a second set of Lights-On/Lights-Off probes.

### Claim 14 (depends on 13)

The method of claim 13, wherein the first set of Lights-On/Lights-Off probes and the second set of Lights-On/Lights-Off probes are tagged with the same fluorescent label.

### Claim 15 (depends on 13)

The method of claim 13, wherein the first set of Lights-On/Lights-Off probes and the second set of Lights-On/Lights-Off probes are tagged with different fluorescent labels.

### Claim 16 (depends on 1)

The method of claim 1, further comprising the step of purifying the DNA molecule such that it is substantially protein-free prior to step a).

### Claim 17 (depends on 16)

The method of claim 16, wherein the purification step is performed using a proteinase K lysis solution containing 10 mM Tris-Cl pH 8.3, 5 μM SDS, and 0.1 mg/ml Proteinase K.

### Claim 18 (depends on 1)

The method of claim 1, wherein the DNA molecule is fragmented prior to step a).

### Claim 19 (depends on 18)

The method of claim 18, where the DNA is fragmented using a restriction enzyme that cuts the DNA molecule outside of the region amplified in step b).

### Claim 20 (depends on 1)

The method of claim 1, wherein at least 90% of unmethylated cytosine residues in the DNA molecule are converted to uracil during step a) and less than 10% of methylated cytosine residues are converted to uracil during step a).

### Claim 21

A method of detecting the methylation status of a CpG dinucleotide located in a target region, the method comprising the steps of:
a) dividing a genomic DNA sample into a control genomic DNA solution containing a control DNA molecule containing the target region from a test genomic DNA solution containing a test DNA molecule containing the target region;
b) contacting the test DNA molecule with a solution comprising bisulfite under conditions such that a majority of unmethylated cytosine residues in the DNA molecule are converted to uracil and a majority of methylated cytosine residues in the DNA molecule remain cytosine;
c) amplifying the target region of the test DNA molecule using LATE-PCR or LEL-PCR using a first primer set complementary to bisulfite treated DNA to generate a first amplification product;
d) amplifying the target region of the control DNA molecule using LATE-PCR or LEL PCR using a second primer set complementary to native DNA to generate a second amplification product;
e) incubating the first amplification product with a first set of Lights-On/Lights-Off probes or with a Lights-Off Only probe and a dsDNA fluorescent dye at different temperatures to generate a first fluorescent signature;
f) incubating the second amplification product with a second set of Lights-On/Lights-Off probes or with a second Lights-Off Only probe and a dsDNA fluorescent dye to generate a second fluorescent signature; and
g) comparing the first fluorescent signature with the second fluorescent signature to determine whether the CpG dinucleotide was methylated.

### Claim 22 (depends on 21)

The method of claim 21, wherein LATE-PCR is used in steps c) and d).

### Claim 23 (depends on 21)

The method of claim 21, wherein LEL-PCR is used in steps c) and d).

### Claim 24 (depends on 21)

The method of claim 21, wherein TI-PCR is used to perform the LATE-PCR or LEL-PCR amplification.

### Claim 25 (depends on 21)

The method of claim 21, wherein one or more SuperSelective primers are used during the amplification process of steps c) and d).

### Claim 26 (depends on 21)

The method of claim 21, wherein the target region encompasses a CpG island.

### Claim 27 (depends on 21)

The method of claim 21, wherein the methylation status of more than one CpG dinucleotide located in the target region is detected.

### Claim 28 (depends on 21)

The method of claim 21, further comprising the step of purifying the DNA molecule such that it is substantially protein-free prior to step a).

### Claim 29 (depends on 28)

The method of claim 28, wherein the purification step is performed using a proteinase K lysis solution containing 10 mM Tris-Cl pH 8.3, 5 μM SDS, and 0.1 mg/ml Proteinase K.

### Claim 30 (depends on 21)

The method of claim 21, wherein the DNA molecules are fragmented prior to step a).

### Claim 31 (depends on 30)

The method of claim 30, where the DNA molecules are fragmented using a restriction enzyme that cuts the DNA molecule outside of the region amplified in step b).

### Claim 32 (depends on 21)

The method of claim 21, wherein at least 90% of unmethylated cytosine residues in the DNA molecule are converted to uracil during step b) and less than 10% of methylated cytosine residues are converted to uracil during step a).
